Inactivir® SDI has the same non-guanidine inactivation system as Inactivir® SD, but also contains buffer components that inactivate nucleotide degrading enzymes including RNAses. Inactivir® SDI also includes an additional chaotrope along with the non-guanidine inactivation system. This provides excellent stability for samples and allows the sample to be used directly in silica-based purification systems.



The LSG Viral Inactivation Buffer Inactivir®, developed in collaboration with the University of Bedfordshire, has been formulated to provide a buffer that will inactivate viruses such as Covid-19, seasonal influenza, SARS, MERS and Ebola.

The use of samples collected in Inactivir® will increase laboratory throughput by reducing the requirement for Category 2+/3 handling of potentially pathogenic samples, increasing the speed and ease of testing. This formulation has been validated by Public Health England.

KEY BENEFITS:

• Any viral particles within the patients samples contained within the tube are inactivated and rendered non-pathogenic.

• Samples do not need to be maintained at +4°C, removing the need for a cold chain in handling.

• The buffer components are widely compatible with current RNA extraction protocols and can be used without disruption to current processing protocols.

• The buffer acts as a stabiliser since the formulation will destroy the enzymes and proteins (including RNAses) which are responsible for the degradation of the RNA/DNA.

• Does not contain PCR inhibitors.